What is claimed:

1. A siRNA molecule that reduces expression of the TGFβ type II receptor, wherein the molecule is 19-25 base pairs in length.

2. A siRNA molecule of claim 1, wherein the molecule has a guanine-cytosine content ranging from 40% to 50% and does not have four identical consecutive bases.

3. A siRNA molecule of claim 1, wherein the siRNA molecule comprises a nucleic acid sequence selected from the group consisting of the nucleic acid sequence of SEQ ID NO: 5, the nucleic acid sequence of SEQ ID NO: 6, the nucleic acid sequence of SEQ ID NO: 7, the nucleic acid sequence of SEQ ID NO: 8, the nucleic acid sequence of SEQ ID NO: 9, the nucleic acid sequence of SEQ ID NO: 10, the nucleic acid sequence of SEQ ID NO: 11, the nucleic acid sequence of SEQ ID NO: 12, the nucleic acid sequence of SEQ ID NO: 14, the nucleic acid sequence of SEQ ID NO: 15, the nucleic acid sequence of SEQ ID NO: 17, the nucleic acid sequence of SEQ ID NO: 18, the nucleic acid sequence of SEQ ID NO: 20, the nucleic acid sequence of SEQ ID NO: 21, the nucleic acid sequence of SEQ ID NO: 23, the nucleic acid sequence of SEQ ID NO: 24, the nucleic acid sequence of SEQ ID NO: 26, the nucleic acid sequence of SEQ ID NO: 27, the nucleic acid sequence of SEQ ID NO: 29, the nucleic acid sequence of SEQ ID NO: 30, the nucleic acid sequence of SEQ ID NO: 32, the nucleic acid sequence of SEQ ID NO: 33, the nucleic acid sequence of SEQ ID NO: 35, the nucleic acid sequence of SEQ ID NO: 36, the nucleic acid sequence of SEQ ID NO: 38, the nucleic acid sequence of SEQ ID NO: 39, the nucleic acid sequence of SEQ ID NO: 41, the nucleic acid sequence of SEQ ID NO: 42, the nucleic acid sequence of SEQ ID NO: 44, the nucleic acid sequence of SEQ ID NO: 45, the nucleic acid sequence of SEQ ID NO: 47, the nucleic acid sequence of SEQ ID NO: 48, the nucleic acid sequence of SEQ ID NO: 50, the nucleic acid sequence of SEQ ID NO: 51, the nucleic acid sequence of SEQ ID NO: 53, the nucleic acid sequence of SEQ ID NO: 54, the nucleic acid sequence of SEQ ID NO: 56, the nucleic acid sequence of SEQ ID NO: 57, the nucleic acid sequence of SEQ ID NO: 58, the nucleic acid sequence of SEQ ID NO: 59, the nucleic acid sequence of SEQ ID NO: 61, the nucleic acid sequence of SEQ ID NO:

62, the nucleic acid sequence of SEQ ID NO: 64, the nucleic acid sequence of SEQ ID NO: 65, the nucleic acid sequence of SEQ ID NO: 67, the nucleic acid sequence of SEQ ID NO: 68, the nucleic acid sequence of SEQ ID NO: 70, the nucleic acid sequence of SEQ ID NO: 71, the nucleic acid sequence of SEQ ID NO: 73, the nucleic acid sequence of SEQ ID NO: 74, the nucleic acid sequence of SEQ ID NO: 76, the nucleic acid sequence of SEQ ID NO: 77, the nucleic acid sequence of SEQ ID NO: 79, the nucleic acid sequence of SEQ ID NO: 80, the nucleic acid sequence of SEQ ID NO: 81 the nucleic acid sequence of SEQ ID NO: 82, the nucleic acid sequence of SEQ ID NO: 84, the nucleic acid sequence of SEQ ID NO: 85, the nucleic acid sequence of SEQ ID NO: 87, the nucleic acid sequence of SEQ ID NO: 88, the nucleic acid sequence of SEQ ID NO: 90, the nucleic acid sequence of SEQ ID NO: 91, the nucleic acid sequence of SEQ ID NO: 93, the nucleic acid sequence of SEQ ID NO: 94, the nucleic acid sequence of SEQ ID NO: 96, the nucleic acid sequence of SEQ ID NO: 97, the nucleic acid sequence of SEQ ID NO: 99, the nucleic acid sequence of SEQ ID NO: 100, the nucleic acid sequence of SEQ ID NO: 101, the nucleic acid sequence of SEQ ID NO: 102, the nucleic acid sequence of SEQ ID NO: 104, the nucleic acid sequence of SEQ ID NO: 105, the nucleic acid sequence of SEQ ID NO: 107, the nucleic acid sequence of SEQ ID NO: 108, the nucleic acid sequence of SEQ ID NO: 110, the nucleic acid sequence of SEQ ID NO: 111, the nucleic acid sequence of SEQ ID NO: 113, the nucleic acid sequence of SEQ ID NO: 114, the nucleic acid sequence of SEQ ID NO: 116, the nucleic acid sequence of SEQ ID NO: 117, the nucleic acid sequence of SEQ ID NO: 119, the nucleic acid sequence of SEQ ID NO: 120, the nucleic acid sequence of SEQ ID NO: 122, the nucleic acid sequence of SEQ ID NO: 123, the nucleic acid sequence of SEQ ID NO: 125, the nucleic acid sequence of SEQ ID NO: 126, the nucleic acid sequence of SEQ ID NO: 128, the nucleic acid sequence of SEQ ID NO: 129, the nucleic acid sequence of SEQ ID NO: 131, the nucleic acid sequence of SEQ ID NO: 132, , the nucleic acid sequence of SEQ ID NO: 134, the nucleic acid sequence of SEQ ID NO: 135, the nucleic acid sequence of SEQ ID NO: 137, the nucleic acid sequence of SEQ ID NO: 138, the nucleic acid sequence of SEQ ID NO: 140, the nucleic acid sequence of SEQ ID NO: 141, the nucleic acid sequence of SEQ ID NO: 143, the nucleic acid sequence of SEQ ID NO: 144, the nucleic acid sequence of SEQ ID NO: 146, the nucleic acid sequence of SEQ ID NO: 147, the nucleic acid sequence of SEQ ID NO: 149, the nucleic acid sequence of SEQ ID NO: 150, the nucleic acid sequence of SEQ ID NO:

152, the nucleic acid sequence of SEQ ID NO: 153, the nucleic acid sequence of SEQ ID NO: 155, and the nucleic acid sequence of SEQ ID NO: 156.

4. A composition comprising the siRNA molecule of any one of claims 1-3 and a pharmaceutically acceptable carrier.

5. The composition of claim 4, wherein the composition further comprises an additional wound healing agent.

6. A method for promoting wound healing in a mammal comprising administering a therapeutically effective amount of the composition of claim 3 or 4 to a mammal in need thereof.

7. A method for inhibiting fibrosis in a mammal comprising administering a therapeutically effective amount of the composition of claim 4 or 5 to a mammal in need thereof.

8. A method for inhibiting angiogenesis in a mammal comprising administering a therapeutically effective amount of the composition of claim 4 or 5 to a mammal in need thereof.

6. A method of any one of claims 6, 7 or 8 wherein the mammal in need is suffering from glaucoma, macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, scarring of the cornea or scarring of the conjunctiva.

7. A method of preventing glaucoma in a mammal comprising administering to said mammal a composition comprising an siRNA molecule that reduces expression of the TGFβ type II receptor, wherein the molecule is 19-25 base pairs in length.

8. A method of preventing restenosis in a mammal comprising administering to said mammal a composition comprising an siRNA molecule that reduces expression of the TGFβ type II receptor, wherein the molecule is 19-25 base pairs in length.

10. A method of preventing or treating scarring in a mammal comprising administering to said mammal a composition comprising an siRNA molecule that reduces expression of the TGFβ type II receptor, wherein the molecule is 19-25 base pairs in length.

11. The method of claim 10, wherein said scarring is coronary vessel scarring.